ReviewJournal of clinical medicine2022
Asian Race and Primary Open-Angle Glaucoma: Where Do We Stand?
Review in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 21 citations in OpenAlex.
- Medical and surgical treatment management in open angle glaucoma patients of Asian descent: A narrative review.European journal of ophthalmology · 2025Review
- Longitudinal changes in the intraocular pressure and their related factors among adults aged 40 to 64 years.Scientific reports · 2025Article
- Taiwan's first clinical reports on the surgical effect of high-frequency deep sclerotomy for treating primary open-angle glaucoma.BMC ophthalmology · 2025Article
- Therapeutic Potential of Tocopherol and Tocotrienol in Glaucoma Management.Drug design, development and therapy · 2025Review
- Genetic polymorphisms of antioxidant enzymes (GSTP1/CAT/HMOX1/EPHX1) and childhood asthma risk in Fuzhou.Frontiers in pediatrics · 2025Article
- Inhibition of TGF-β2-Induced Trabecular Meshwork Fibrosis by Pirfenidone.Translational vision science & technology · 2023Article
- Metabolic syndrome as an independent risk factor for glaucoma: a nationally representative study.Diabetology & metabolic syndrome · 2023Article
- Immunomodulatory and Antioxidant Drugs in Glaucoma Treatment.Pharmaceuticals (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
Abstract
Primary open-angle glaucoma (POAG) is an optic neuropathy characterized by irreversible retinal ganglion cell damage and visual field loss. The global POAG prevalence is estimated to be 3.05%, and near term is expected to significantly rise, especially within aging Asian populations. Primary angle-closure glaucoma disproportionately affects Asians, with up to four times greater prevalence of normal-tension glaucoma reported compared with high-tension glaucoma. Estimates for overall POAG prevalence in Asian populations vary, with Chinese and Indian populations representing the majority of future cases. Structural characteristics associated with glaucoma progression including the optic nerve head, retina, and cornea are distinct in Asians, serving as intermediates between African and European descent populations. Patterns in IOP suggest some similarities between races, with a significant inverse relationship between age and IOP only in Asian populations. Genetic differences have been suggested to play a role in these differences, however, a clear genetic pattern is yet to be established. POAG pathogenesis differs between Asians and other ethnicities, and it may differ within the broad classification of the Asian race. Greater awareness and further research are needed to improve treatment plans and outcomes for the increasingly high prevalence of normal tension glaucoma within aging Asian populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.